Skip to main
ENGN

ENGN Stock Forecast & Price Target

ENGN Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 38%
Hold 38%
Sell 0%
Strong Sell 0%

Bulls say

enGene Therapeutics is currently facing some challenges with their latest clinical trial data, however, their overall approach using their DDX platform is still promising, as demonstrated by the positive preclinical data on polidocanol for enhancing urothelial transfection. Additionally, their strong cash position of $285.2 million and management's decisions to conserve capital and re-evaluate their clinical trial strategy show responsible financial management. While the updated interim data for the LEGEND Phase 2 trial of detalimogene in NMIBC is concerning, enGene Therapeutics remains a solid investment opportunity with a potential role in the treatment of high-risk non-muscle invasive bladder cancer.

Bears say

enGene Therapeutics is focused on developing a gene therapy treatment for bladder cancer, but the company is facing challenges in the near-term with a lackluster data update and uncertainty surrounding the future of its CMO. There are also doubts about whether the company's treatment can achieve a competitive profile, with a current estimate for the 12-month complete response rate sitting at 24.5%. With these concerns in mind, our outlook on the company's stock is negative, and we have downgraded it to Neutral with a $4/sh PT.

ENGN has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 38% recommend Buy, 38% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Engene Holdings Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Engene Holdings Inc (ENGN) Forecast

Analysts have given ENGN a Buy based on their latest research and market trends.

According to 8 analysts, ENGN has a Buy consensus rating as of Aug 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.94, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.94, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Engene Holdings Inc (ENGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.